After Mary died, several people had talked about
how I should do a book of her paintings. I had started out thinking
I would just do a limited edition set of boxed prints, but costs
were exorbitant unless I only wanted to print about 20 sets, which
clearly wasn't enough.
...At first I thought a paperback book would be
enough, and then I worried about the quality of
the prints, and I didn't think anyone would respect
her artwork if I did it as a paperback....read
rest of story...
North Carolina man going strong 20 years after rare,
risky surgery
Vann Matthews has lived longer than almost anyone
with a transplanted heart and lung, and as remarkable
as that is, so is his wife's devotion.
Alice
stood by her man.
They were college sweethearts when Vann was diagnosed
in 1981 with a rare and incurable disorder that wears
out the lungs and the heart. A double-transplant was
his only hope.
Until then, there had been only one heart-lung transplant.
Ever. Not only was the operation risky, there was
no national clearinghouse for organs, so donors were
hard to find.
Myogen
Announces Publication
of Ambrisentan Data in Two Scientific Journals
DENVER, Aug. 11 /PRNewswire-FirstCall/
-- Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical
company focused on the discovery, development and commercialization
of small molecule therapeutics for the treatment of cardiovascular
disorders, today announced the publication of the results
from a Phase 2 trial of ambrisentan in patients with pulmonary
arterial hypertension (PAH) in this month's issue of the
Journal of the American College of Cardiology. In addition,
this month's issue of Future Cardiology contains a review
article describing the potential of ambrisentan as a new
treatment for patients with PAH.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information resource
for people dealing with PH -- they have ARRIVED and are ready to
ship!!!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Ronald J. Oudiz and a team of physicians with a deep
knowledge of PH edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials;
in-depth discussion of PH secondary to other diseases
or conditions;
a new chapter on what to eat if you have PH; and much, much more!
Actelion: Second Study with bosentan (Tracleer) Demonstrating a Statistically Significant Reduction of New Digital Ulcers in Patients with Systemic Sclerosis
ALLSCHWIL, Switzerland, Aug. 9, 2005 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX: ATLN) announced today the preliminary result of a double-blind, placebo-controlled, randomized, multi-center, 190-patient Phase III study, RAPIDS-2, with the dual endothelin receptor antagonist bosentan (Tracleer(R)) in systemic sclerosis patients suffering from digital ulceration.
For
Medical Professionals:
With the advent of new PH drugs and treatments, more
and more doctors are becoming increasingly involved
in the PH community. PHA has responded to this, and
will bring together world-renowned leading PH specialists
to lead Medical Education Sessions for their peers
during the fall in six cities: New York; Atlanta;
Chicago; Seattle; Dallas; and Washington, DC
Physicians
who participate
are eligible to receive CME credits. Educational credits
will also be available for nurses and pharmacists.
For questions
or to register by phone, please call 858-717-2940.
For Patients:
While we are bringing together leading specialists
and interested medical professionals for the Medical
Education Sessions, we know that patients will also
greatly benefit from these gatherings. We are therefore
very excited to announce PHA's Regional Patient Education
Sessions.
Many of the medical professionals presenting earlier
during the day will stay for the evening's PHA Regional
Patient Education Session to participate in a dinner,
educational slide-show and panel discussion of current
advances in PH. Kim Bernstein, director of ACCESS,
will also be at each session, presenting on insurance
issues and how to use her program as an important
resource.
Partnering with Actelion and Accredo
Therapeutics we are able to allow a free ticket to
each patient and one guest (a 50 dollar value), up
to the first 200 registrants. This includes dinner
and the presentations. Any additional guests or registrations
after the first 200, will need to purchase a ticket
at $25. PH patients with Scleroderma are also invited
to attend a Scleroderma Support Group meeting taking
place earlier in the day.
PHA thanks Actelion, our primary sponsor,
and Accredo Therapeutics for their generous support
of this program.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
